News Sentiment

EVMN sentiment intelligence

Evommune, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 43 Balanced news tone 26 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.14 Week of 17 Jul 2026
Weighted tone 43/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

73/100 classification confidence.

Company focus 17

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.1% over one week, -43.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 73/100 classification
One-week reaction -8.1% Price reacting lower
Trend fit Trend inactive -43.2% over four weeks
Fair value -42.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 12
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 17
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 3
MarketBeat 3
Moomoo 2
Stock Titan 2
simplywall.st 2
TipRanks 1
Seeking Alpha 1

Event Lens

What the news is about

Classified themes
Earnings 11
Market update 8
Analyst action 3
Regulatory and legal 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-26 of 26
TradingView Direct company coverage

Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD

This article focuses on the long-term debt to total assets ratio of Evommune, Inc. (BX:EVMNUSD), providing financial data for the company. The content appears to be a financial data page from TradingView, without additional analytical text or detailed news. It simply presents the

Tone
Neutral 50/100
Event
Balance sheet
Published
21 Jul 2026 05:10
Source
TradingView
MarketBeat Direct company coverage

Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages

Evommune, Inc. (NYSE:EVMN) has received a "Moderate Buy" consensus rating from 14 brokerages, with an average 1-year price target of $45.63, despite a mixed outlook including one sell, three holds, eight buys, and two strong buys. The stock is trading near its 52-week low of $12.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 08:41
Source
MarketBeat
MarketBeat Direct company coverage

Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock

Evommune's CFO, Kyle Carver, recently purchased 1,000 shares of the company's stock for $13.26 per share, totaling $13,260. This acquisition increased his direct holdings to 60,335 shares, following a sale of 18,175 shares in late May. The transaction occurred while EVMN shares w

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jul 2026 01:10
Source
MarketBeat
MarketBeat Direct company coverage

Evommune (NYSE:EVMN) Director Acquires $133,000.00 in Stock

Evommune (NYSE:EVMN) Director Arthur Kirsch recently purchased 10,000 shares of the company's stock for $133,000, bringing his total ownership to 10,000 shares. This transaction occurred on July 7th at an average price of $13.30 per share. Despite the insider buying, EVMN shares

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 01:10
Source
MarketBeat
Moomoo Direct company coverage

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Levi & Korsinsky is investigating potential securities fraud claims against Evommune, Inc. (EVMN) on behalf of its shareholders. The investigation focuses on whether the company or its officers engaged in misleading business practices. Shareholders who suffered losses are encoura

Tone
Negative 9/100
Event
Regulatory and legal
Published
08 Jul 2026 03:10
Source
Moomoo
Moomoo Direct company coverage

Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54

Stifel has reiterated its Buy rating for Evommune (EVMN.US) and maintained a target price of $54. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.

Tone
Positive 70/100
Event
Analyst action
Published
06 Jul 2026 11:10
Source
Moomoo
TipRanks Direct company coverage

Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market

Evommune, Inc. announced the completion of its Phase 2b trial for EVO756, an oral drug designed to treat moderate to severe chronic spontaneous urticaria. This milestone is crucial for investors as positive results could pave the way for a larger Phase 3 program and potential par

Tone
Positive 61/100
Event
Earnings
Published
01 Jul 2026 16:10
Source
TipRanks
The Dermatology Digest Direct company coverage

Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development

Evommune, Inc.'s oral MRGPRX2 antagonist, EVO756, failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to discontinue its development for this indication. Despite this setback, Evommune plans to continue evaluating E

Tone
Negative 19/100
Event
Market update
Published
30 Jun 2026 21:39
Source
The Dermatology Digest
PR Newswire Direct company coverage

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Levi & Korsinsky, LLP has initiated an investigation into the officers and directors of Evommune, Inc. (EVMN) following a significant stock drop. This investigation concerns insider stock sales by the CEO and CSO that occurred just days before the company publicly announced that

Tone
Negative 10/100
Event
Regulatory and legal
Published
30 Jun 2026 17:41
Source
PR Newswire
Stock Titan Direct company coverage

Evommune (NYSE: EVMN) halts EVO756 CSU program after Phase 2b miss

Evommune (NYSE: EVMN) announced the discontinuation of its EVO756 program for chronic spontaneous urticaria (CSU) following a Phase 2b trial failure. The study, which enrolled 160 patients, did not meet its primary endpoint of mean change in Urticaria Activity Score over seven da

Tone
Negative 18/100
Event
Market update
Published
30 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

EVO756 trial miss, Evommune (NYSE: EVMN) shifts focus to AD and migraine

Evommune (NYSE: EVMN) announced that its oral drug EVO756 failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to halt further development for that indication. Despite this setback, Evommune will continue evaluating

Tone
Negative 35/100
Event
Market update
Published
30 Jun 2026 00:10
Source
Stock Titan
TradingView Direct company coverage

Evommune, Inc. Stock 12‑Month Price Target Cut to $39.33, Implies 56% Upside

Evommune, Inc. (EVMN) has seen its average 12-month price target reduced from $45.22 to $39.33 by analysts, though this new target still suggests approximately 56% potential upside from the June 26 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts

Tone
Positive 70/100
Event
Analyst action
Published
29 Jun 2026 22:20
Source
TradingView
www.marketscreener.com Direct company coverage

Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark

Evommune, Inc. (NYSE: EVMN), a clinical-stage biotechnology company, has been removed from the Russell 2000 Value Benchmark, alongside being dropped from several other Russell indices. This news coincides with recent reports of the company's EVO756 Phase 2b trial in chronic spont

Tone
Negative 16/100
Event
Market update
Published
29 Jun 2026 18:12
Source
www.marketscreener.com
Business Wire Direct company coverage

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Evommune, Inc. announced that its Phase 2b trial for EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU) did not meet its primary endpoint. Despite this, the company plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data for atopic

Tone
Negative 29/100
Event
Earnings
Published
29 Jun 2026 12:12
Source
Business Wire